Tagged with Vaccines

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

Global While COVID-19 demonstrated the biopharma industry’s capacity for innovation and its ability to scale up manufacturing, it also exposed the challenges of ensuring equitable distribution of vaccines. In an effort to work towards solving these issues and being better prepared to respond to future pandemics, the industry has created the…

Global Since monkeypox was declared a global emergency by the World Health Organization (WHO) and industrialized countries began stockpiling vaccines, Bavarian Nordic’s shares have more than tripled while Siga Technologies has seen the value of its stock double.   … we are pleased to assist more countries with supply of vaccines…

Italy Paivi Kerkola, Country Manager, Managing Director and President of Pfizer Italy, speaks about the peculiarities of the Italian market from a northern European perspective, her priorities, and the impact of the COVID-19 pandemic and how it not only put Pfizer in the spotlight but also triggered an unprecedented dialogue between…

Canada Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the Public Health Agency of Canada’s recent smallpox contracts with Chimerix and Bavarian Nordic.   GSK flu vaccine deal renewal (Reuters)…

Global Due to lowered global demand, for the first time, Pfizer/BioNTech and Moderna are expected to see sales revenues for their COVID-19 vaccines take a major fall in Q2, but sales are expected to bounce back with jabs targeting new variants. According to Airfinity’s recent forecast, revenue for Pfizer/BioNTech’s vaccine will…

Global GSK has separated itself from its consumer healthcare business, newly named Haleon, home to brands such as Sensodyne and Advil. Now what? After underperforming in recent years, a few clinical trials fails and a resulting push for change from its investors, the breakup with its consumer healthcare arm was long-announced…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Africa David Mukanga of the Bill and Melinda Gates Foundation gives an overview of the latest developments on the long road towards the creation of an African Medicines Agency and the push to establish vaccine manufacturing facilities on the continent.   Since the minimum number of 15 ratifications by African Union…

China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…

United Kingdom US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion in profit for the firm last year – has announced a new GBP one billion investment into a UK manufacturing…

Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives.  Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…